Wheeze and cough measurements at night in children with respiratory symptoms

Markus Lindenhofer1,2, Lena Roth2, Clemens Mädel2, Florian Götzinger2, Katharina Kainz2, Christiane Lex3, Thomas Frischer2,4, Matthias Reinweber5 and Angela Zacharasiewicz2*

Abstract

Background: Nocturnal cough and wheeze are important symptoms when diagnosing any respiratory disease in a child, but objective measurements of these symptoms are not performed.

Methods: The aim of our study was to analyze the use of an automated detection system to assess breath sounds objectively in comparison to cough and wheezing questionnaires and to evaluate its feasibility in clinical practice.

Results: Forty-nine recordings of thirty-nine children were processed (asthma n = 13; cystic fibrosis n = 2; pneumonia n = 5; suspicion of habit cough n = 7; prolonged, recurrent or chronic cough n = 13), and cough and asthma scores were compared to the objective nocturnal recordings. Time for audio-validation of recordings took between 2 and 40 min (mean: 14.22 min, (SD): 10.72). Accuracy of the automated measurement was higher for cough than for wheezing sounds. Nocturnal cough readings but not wheeze readings correlated with some of the corresponding scores.

Conclusion: To our knowledge this is the first study using a new device to assess nocturnal cough and obstructive breath sounds objectively in children with a wide variety of respiratory diseases. The assessment proved user friendly. We obtained additional information on nighttime symptoms, which would otherwise have remained obscure. Further studies to assess possible diagnostic and therapeutic benefits of this device are needed.

Keywords: Cough, Wheeze, Cough monitor, Nocturnal symptoms, Children
negative effects of those undetected and hence untreated symptoms on the patients’ quality of life may occur [10–12]. Especially during COVID 19 pandemic uncontrolled asthma is an important risk factor for severe COVID-19 disease [13]. Thus, nocturnal wheeze, if detected early, should initiate appropriate therapy [14]. The Task Force of the European Respiratory Society on asthma monitoring concludes that different types and stages of asthma require different types of monitoring schemes [15]. While various biomarkers are currently used on asthma control, further investigations are needed on the impact of nocturnal cough and wheeze [15–18].

Acute pneumonia is an infection of the pulmonary interstitium and the alveoli. Fever, cough and/or shortness of breath are common symptoms with frequency and severity of cough differing between individuals and changing over the time course of the disease [19]. Little information is currently available on nocturnal cough frequency in children with pneumonia.

Cystic fibrosis (CF) is an inherited autosomal recessive disorder, mostly diagnosed at young age due to expanding newborn screenings [20] with clinical manifestation differing in individuals. However, lung disease usually is present from the early life [21] and a vicious circle of infection and inflammation in the lung causes pulmonary exacerbations resulting in progressive deterioration of lung function [22].

In children prolonged, recurrent or chronic cough can be the symptom of many underlying respiratory systemic diseases. Knowledge of the objective quantity of the symptoms cough and wheezing at night may provide useful information both for the decision making for appropriate diagnostic measurements and necessary therapeutic agents [23].

Psychogenic cough mostly presenting with dry cough is usually non-existent at night [24, 25] and the diagnosis is made after excluding all other causes of chronic cough [23, 26].

Questionnaires for patients and parents [14, 27] have been developed to evaluate nocturnal, respiratory symptoms, and have shown partially good results. Still, compared to objective methods they are inconsistent [28]. Devices like the Leicester Cough Monitor or the Vitalo-Jak offer an objective display of cough frequency [29–31], but none of these devices are used to detect nocturnal wheezing [32]. Our intention was to assess cough and wheezing at night in children suffering from various both acute and chronic respiratory diseases using a new automated detection device.

The LEO-Sound System may offer the possibility to perform objective and repeatable measurement of cough and wheezing frequency [33–38].

Therefore, the rational and aim of this study was to assess this new method of collecting additional information about the patients’ nighttime symptoms of cough and wheeze by firstly comparing audio recordings with questionnaire data and secondly by assessing the overall feasibility of this method in clinical practice.

**Methods**

**Subjects**

Both in- and out-patients aged 4 to 18 were enrolled for this study. Inclusion criteria were current respiratory symptoms such as cough, wheeze or shortness of breath. We excluded patients, who were respiratory unstable and needed intensive care and those with the detection of multiresistant pathogens, such as methicillin-resistant *staphylococcus aureus* (MRSA), oxacillin-resistant *staphylococcus aureus* (ORSA), vancomycin-resistant *staphylococcus aureus* (VRSA), glycopeptide-resistant enterococci (GRE), vancomycin-resistant enterococci (VRE), multidrug resistant Gram-negative bacteria (MRGN) and extended-spectrum beta-lactamase (ESBL).

The study was approved by the Local Ethics Committee and written informed consent was obtained from participating children, adolescents and caretakers.

**Study design**

All recordings using the Leo-Sound monitor were done overnight in an inpatient or outpatient setting, during 8 h of night sleep in the first 29 patients and for 10 h in the remaining 10 patients, due to getting the experience of higher practicability with longer recording time. The monitor was attached to each patient by medically trained personal. In the outpatient setting, recordings were performed at home and the devices were returned to the hospital for analyses. Current symptoms were evaluated before and after the measurement by medical doctors, using validated scores and questionnaires (see below). The Leo-Sound-Analyzer (Löwenstein Medical GmbH & Co. KG, Bad Ems, Germany) analyzes recordings automatically. All breath sounds, which were classified as cough or wheeze by the Leo-Sound Analyzer, were thereafter manually checked for accuracy and plausibility by a medically trained observer listening to the detected sounds. For continuity, the same two observers validated the recordings. Time needed for audio-validation of the recordings was noted.

**Leo-Sound**

The Leo-Sound Lung-Sound-Monitor (Löwenstein Medical GmbH & Co. KG, Bad Ems, Germany) is a 35 mm × 75 mm × 170 mm (H x W x L) big device that was developed to objectively record and analyze cough and wheezing for a maximum duration of 24 h. Three microphones were placed on the skin in the area of the trachea – for distinguishing cough sounds – and both lungs to record the patient’s respiratory sounds (Fig. 1).
The spots for the two microphones on the back were chosen after auscultation was done on each patient. Results of this examination were not taken into account for analysis. After the measurement was completed the monitor was connected to an HP ProBook laptop and the recordings were automatically analyzed by the LeoSound-Analyzer®. The program searches for frequencies and amplitudes specific for cough and wheeze, respectively. Identified respiratory sounds were then illustrated on a timeline, afterwards, the sounds identified as cough and wheeze were then assessed for measurement validation manually. In the process of validating the automated analyses, sounds like snoring, harrumphs, talking by the patient, alarm signals of other monitors, background noise or bowel movement have been found to mimic coughing and wheezing, respectively. Data of both the absolute number of lung sounds and the amount of 30-s periods, in which lung sounds were identified, were obtained, before and after validation by an observer. False negative coughs and wheezes were not further assessed. It should be noted that the analyzing program did not distinguish between wheezing at inspiration and wheezing at expiration. Therefore, wheezing sounds were further assessed, and distinguished manually whether they occurred during inspiration or expiration. Both wheezing at inspiration and expiration as well as wheezing at expiration-only were analyzed.

**Questionnaires**

The evaluation by means of scores and questionnaires was done in three stages (Fig. 2). Firstly, before the recording, two VCD (verbal category descriptive) scores developed by Chang et al. [28] covering cough at daytime (VCD-D) and cough at nighttime (VCD-N) were used to evaluate severity and frequency of cough in our patients. Cough at daytime was evaluated to see if a correlation with nighttime symptoms could be observed. Only participants diagnosed with asthma were also given the Asthma Control Test (ACT) [39, 40] to determine asthma control over the last 4 weeks. Patient characteristics regarding age, gender, current medication and exposure to secondhand smoking were obtained. Additionally, FEV1 and the Tiffeneau index from prior lung function tests were obtained, if recent data was available.

The second stage took place during the recording: Children, who were assessed in an inpatient setting were evaluated additionally by the nursing staff in terms of the perception of cough and/or other breath sounds every 2 h, using a newly developed, simplified score (Score-NS) that has not yet been validated.

At stage three – after the recording – all caregivers/families who spent the night of the recording at home or on the ward with their children were given a simplified translated version of the validated pediatric cough questionnaire (PCQ) developed by Hartnick, et al. [41] to capture the parent’s perception of their children’s nocturnal symptoms during the recording. The last ten patients were also evaluated using the main parts of a validated parent-proxy quality of life questionnaire for pediatric chronic cough (PC-QoL), developed by Newcombe et al. [42], which was translated into German language.

**Statistical analysis**

Depending on the variable’s distribution continuous data are either expressed as means and standard deviation (SD) or median and interquartile range (IQR) and were analyzed with multivariate analysis of variance (MANOVA) and Pearson-Correlation respectively. Categorical variables are expressed in absolute numbers and percentages. Normality-tests have been measured using the
Kolmogorov-Smirnov test (KS-test) und homogeneity of variance was proved using Levene’s test of homogeneity of variance. Posthoc-testing was performed using the Bonferroni corrected z test. Results were categorized as statistically significant with an alpha level set < 0.05 and < 0.01; the reported p-values are two-sided. All analyses were performed using SPSS, version 25.0 (IBM Corp, Armonk, NY, USA).

Results
From 47 children matching the inclusion criteria 5 children declined to participate; three were excluded, because of low quality recordings, resulting in n = 39 children with valid measurements (23 males, 16 females; median age 9.53 years, range 4–17 years). Nine children had more than 1 recording and 1 statistical outlier resulting in 49 valid recordings. Nineteen recordings were obtained in an inpatient setting and 30 were done in an outpatient setting (Table 1). If two recordings were done on consecutive nights, the mean of both recordings was taken, as no significant difference between the two measurement nights had been found. All other recordings were analyzed individually. Finally, 43 recordings were used for the statistical analysis.

Data from 20 lung function tests were available for analysis, including 9 sets of data were bronchodilation was used (Table 2). Nine patients had not been prescribed any medication at the time of the recording. All other participants had either been prescribed antibiotics, beta2-sympathomimetic or inhaled glucocorticoids. The mean absolute number of coughs per child post validation was 18.78 (SD: 26.29) per recording. Furthermore, the mean amount of cough episodes (i.e. 30-s-periods in which at least one cough was registered) was 7.17 (SD: 9.31). The absolute number of wheezes per child post-validation was 488.72 (SD: 1048.40) per recording. The mean number of wheezing episodes (i.e. 30-s-periods in which at least one wheeze was registered) was 71.69 (SD: 130.38). Taking just expiratory-only wheezing into account the absolute number of wheezes per child post-validation was 71.34 (SD: 29.72). Some children did not

| Table 1 Demographics of the study population for both recordings and patients |
|---------------------------------|-----------------|-----------------|
|                                  | Recordings (%)  | Patients (%)    |
| All                             | 43 (100%)       | 39 (100%)       |
| Gender                          |                 |                 |
| Male                            | 24 (55.8%)      | 23 (59%)        |
| Female                          | 19 (44.2%)      | 16 (41%)        |
| Location of recording           |                 |                 |
| Inpatient                       | 18 (41.9%)      | N/A             |
| Outpatient                      | 25 (58.1%)      | N/A             |
| Age                             |                 |                 |
| 4–8                             | 19 (44.2%)      | 16 (41%)        |
| 9–13                            | 17 (39.5%)      | 16 (41%)        |
| 14–17                           | 7 (16.3%)       | 7 (18%)         |
| Secondhand smoking              |                 |                 |
| Yes                             | 10 (23.2%)      | 10 (25.6%)      |
| No                              | 27 (62.8%)      | 26 (66.6%)      |

The data of 4 patients, who were recorded twice, but not on consecutive nights, were counted separately, making the difference between n = 39 patients and 43 valid recordings.
register any cough or wheeze. 25.7% of all detected and validated obstructive respiratory sounds were identified as wheezing on expiration only - typical of obstruction within the lung and found in asthmatic children.

Six different questionnaires to assess respiratory symptoms were used; these were subjective tools and 3 of the 6 questionnaire scores used in this study correlated with the cough recordings measured (Table 3). Firstly, the VCD-D, which examines cough at daytime ($r = 0.46$, $p < .01$), and secondly the VCD-N, which examines cough at nighttime ($r = 0.42$, $p < .01$), showed a significant correlation to objective cough recording data. There was also a significant correlation between cough recordings and the nursing staff score, Score-NS ($r = .713$, $p < .05$). The other validated scores – PCQ, the ACT and the PC-QoL – did not show any correlation with the

Table 2 Lung function data and medication of included patient groups

|                        | Asthma | Habit | CF    | Unknown | Pneumonia | All     |
|------------------------|--------|-------|-------|---------|-----------|---------|
| Patients/recordings    | 13/14  | 7/7   | 2/3   | 13/14   | 5/5       | 39/43   |
| Lung function          |        |       |       |         |           |         |
| N=                     | 11     | 4     | 3     | 7       | 1         | 26      |
| FEV1 (L)               | 1,44   | 2,35  | 1,09  | 1,78    | 1,23      | 1,63    |
| FVC (L)                | 2,17   | 2,36  | 1,56  | 2,04    | 1,51      | 2,07    |
| FEV1/FVC (%)           | 68,45% | 92,53%| 67,67%| 86,15%  | 81,00%    | 77,31%  |
| After bronchodilation  |        |       |       |         |           |         |
| N=                     | 8      | 1     | 0     | 1       | 1         | 11      |
| FEV1 (L)               | 1,71   | 1,51  | –     | 2,13    | 1,18      | 1,68    |
| FVC (L)                | 2,33   | 1,66  | –     | 2,29    | 1,47      | 2,19    |
| FEV1/FVC (%)           | 72,70% | 90,81%| –     | 93,05%  | 80,18%    | 76,88%  |
| Medication             |        |       |       |         |           |         |
| Steroids               | 12     | 3     | 0     | 6       | 0         | 21      |
| β-2 sympathomimetics   | 13     | 2     | 3     | 7       | 2         | 27      |
| Antibiotics            | 1      | 0     | 0     | 1       | 4         | 6       |

This table shows the mean of lung function data for both, before and after bronchodilation, if available

FEV1 forced expiratory volume per second, FVC forced vital capacity

*one patient was first included with acute pneumonia and later on again with chronic respiratory symptoms

|                        | VCD-N | VCD-D | ACT  | PCQ  | PC-QoL | Score-NS |
|------------------------|-------|-------|------|------|--------|----------|
| Coughing               |       |       |      |      |        |          |
| N=                     | 35    | 34    | 17   | 19   | 7      | 12       |
| Episodes with cough    | $r$   | 0.48**| 0.41*| 0.05 | 0.07   | −0.33    | 0.42     |
| p-value                |       | 0.00  | 0.02 | 0.85 | 0.76   | 0.47     | 0.17     |
| Number of coughs       | $r$   | 0.42* | 0.46**| 0.07 | 0.08   | −0.26    | 0.71**   |
| p-value                |       | 0.01  | 0.01 | 0.79 | 0.73   | 0.56     | 0.01     |
| Wheezing               |       |       |      |      |        |          |
| N=                     | 34    | 33    | 17   | 19   | 7      | 11       |
| Episodes with wheezing | $r$   | 0.21  | 0.11 | −0.03| −0.07  | −0.44    | 0.07     |
| p-value                |       | 0.23  | 0.52 | 0.89 | 0.78   | 0.32     | 0.84     |
| Number of wheezes      | $r$   | 0.22  | 0.08 | −0.03| −0.07  | −0.43    | 0.08     |
| p-value                |       | 0.22  | 0.66 | 0.90 | 0.78   | 0.34     | 0.82     |
| Wheezes at expiration  | $r$   | 0.11  | 0.15 | 0.06 | −0.07  | 0.69     | 0.09     |
| p-value                |       | 0.56  | 0.43 | 0.81 | 0.78   | 0.13     | 0.78     |

VCD-D verbal category descriptive score for cough at daytime, VCD-N verbal category descriptive score for cough at nighttime, ACT Asthma Control Test, Score-NS score for cough during recording as perceived by nursing staff (only in-patients), PCQ pediatric cough questionnaire, PC-QoL parent-proxy quality of life questionnaire for pediatric chronic cough; p-value: two-tailed p-value of Pearson’s correlation; *: correlation between subjective score and objective recording results with $p < 0.05$; **: correlation with $p < 0.01$
measurements of nocturnal cough. Furthermore, we found no correlation of cough measurements with the lung function parameters FEV₁ and the Tiffeneau index, current medication, recorded passive smoke exposure or other variables like age, gender, or the location of the recording. Finally, none of the questionnaires or other parameters correlated with the nocturnal wheezing recordings.

Measurement of time to manually validate results was recorded in the first 29 patients. The average time for manual validation of a recording was 14.22 min (SD: 10.72 min), ranging from 2 to 40 min. A learning curve was detected \( r = -.398; \ p < .05 \) (Fig. 3) and measurements were double checked independently by two doctors. The automatic-only-evaluation of breath sounds performed better at detecting cough (mean: 59.14%, SD: 33.13%; median: 71.11%, IQR: 36.3–86.3%) than at classifying wheezing sounds correctly (mean: 37.36%, SD: 35.07%; median: 34.5%, IQR: 0–62.25%), meaning, only 59.14% of coughs and 37.36% of wheezing sounds were already interpreted correctly by the used analyzing program prior to manual validation.

**Discussion**

In this study, firstly we demonstrate that the device used (Leo-Sound) can also measure obstructive respiratory sounds like wheeze during sleep setting it apart from other available cough recording devices. Cough monitors like the Leicester Cough Monitor or the VitaloJak have already shown promising results [32, 43], but are restricted to assessing cough, making wheezing again undetected. Secondly, we were able to show that results can be obtained in a user-friendly fashion with an acceptable time to obtain a validated result. The usefulness of the monitoring device was also demonstrated by Grosse-Onnebrink et al. in a study of patients with cystic fibrosis and primary ciliary dyskinesia [36]. Although manual validation was also done in this study, there was no information published on how well the automated analyzing program interpreted respiratory sounds. A study published by Koehler et al. compared subjective and objective assessments of cough in children with acute bronchitis, using the Leo-Sound, and showed a significant correlation between the two [38]. Contrary to those findings, only two of the previously validated scores used in our study correlated with the objective nighttime cough recordings. The VCDs (VCD-D, VCD-N) developed by Chang et al. [28], covering cough at day- and nighttime, respectively, are simple verbal descriptive scores using a scale from 0 to 5 to evaluate the severity of the cough and correlated with objective measurements. The other cough questionnaires did not correlate with the recorded and verified, nocturnal cough amount, demonstrating a poor agreement between subjective and objective assessment. However, overall numbers are small and therefore the results should be interpreted with caution, since the return number of the scores used, excluding the VCDs, was low.

In this study a new in-house score was used, utilizing very simplified evaluations by the nursing staff every 2 h, whether coughing was perceived or not. This score did correlate with the amount of nocturnal cough, however, the number of patients again was small (\( n = 11 \)). Therefore, relying on the assessment of nocturnal cough by

---

**Fig. 3** Time of manual validation. The time of manual validation of the recordings shown chronologically from the first (left) to the last (right).
the nursing staff might be a good alternative to objective recordings, in an in-patient setting only. However, workload of hospital staff and background noise on any busy pediatric ward are limiting factors.

With regards to the measurements of wheezes, the well-established ACT score did not correlate with the results of nocturnal measurements of expiratory wheezing. Therefore, our results further underscore the importance of using objective tools to monitor nighttime symptoms. Nocturnal wheezing measured objectively did not correlate with lung function values of FEV$_1$ or the Tiffeneau index, both before and after bronchodilatation. However, again the results must be interpreted with caution due to the small number of patients. Furthermore, some of the lung function measurements were not performed within a few days to the nocturnal measurement. In 5 children time between the nocturnal measurement and lung function was 2–8 weeks, hence lung function might have been quite different on the day of the nocturnal measurement. In our study, about 40% of coughing events and 60% of wheezing events were initially interpreted falsely by the automated program; this is in contrast to a study published in 2015 by Gross et al., describing the initial sensitivity and specificity for both cough and wheeze without re-listening to sounds manually after recording to verify them to be over 90% [37]. One explanation of the discrepancy was that background noise may have interfered with our measurements in some cases.

Possible obstacles for wider use in clinical practice may be the need to reassess the measurements manually to exclude false positive cough and wheeze events, which we have demonstrated in our study. With training manual validation can be achieved in less than 10 min, which we consider an acceptable time frame in the clinical setting. This is similar to manual checks done after long time measurement such as sleep studies, long term blood pressure of other physiological measurements.

One limitation of our study is the fact, that we were not able to include a control group into our study for comparison. Another limitation of the study is the small sample size and the heterogeneity of the study population. Nevertheless, we have shown that the method described can be used in various pediatric respiratory diseases. Although different separate diagnostic groups are too small to make significant claims about benefits for the patients, our findings are promising. In habit cough patients for instance, demonstration of complete lack of cough during nighttime sleep, confirmed suspected diagnosis in these cases. If and to what extent a recording’s result would affect a child’s treatment or diagnosis, should thus be subject of future studies.

Possible future areas of use may be the adjustment of anti-inflammatory therapy in asthmatic patients and children suffering from various wheezing phenotypes in particular if they are symptomatic at night [44]. Also, treatment optimization in patients with cystic fibrosis and the diagnosis of patients suspected to suffer from psychogenic cough might be possible. Further studies on indication and benefit from the procedure are necessary.

**Conclusion**

In summary, we have shown a discrepancy between nocturnal measurements and most subjective symptom reports by questionnaires. Nocturnal breath sound monitors like the Leo-Sound device used here, seem to be useful measurement tools to objectively assess nocturnal respiratory symptoms in children.

**Abbreviations**

CF: Cystic fibrosis; FEV$_1$: Forced expiratory volume per second; FVC: Forced vital capacity; VCD-D: Verbal category descriptive score for cough at daytime; VCD-N: Verbal category descriptive score for cough at nighttime; ACT: Asthma Control Test; Score-NS: Score for cough during recording as perceived by nursing staff (only in-patients); PCQ: Pediatric cough questionnaire; PC-QoL: Parent-proxy quality of life questionnaire for pediatric chronic cough; SD: Standard deviation; IQR: Inter quartile range; MRSA: Methicillin-resistant staphylococcus aureus; ORSA: Oxacillin-resistant staphylococcus aureus; VRE: Vancomycin-resistant staphylococcus aureus; GRE: Glycopeptide-resistant enterococci; VRE: Vancomycin-resistant enterococci; MRGN: Multidrug resistant Gram-negative bacteria; ESBL: Extended-spectrum beta-lactamase

**Acknowledgements**

Not Applicable.

**Authors’ contributions**

ML helped designing the study, writing the ethics application, recruited patients, performed the sound measurements, coordinated questionnaires, evaluated the automated recordings, coordinated patient visits, and wrote the draft manuscript. LR performed the sound measurements, evaluated the automated recordings, coordinated patient visits, and proofread the manuscript. CM advised on study design, recruited patients, helped with data management and took part in manuscript writing. FG advised in writing the Ethics proposal and helped writing the manuscript. KK took part in data acquisition, patient recruitment and manuscript preparation. CL advised on study design and took part in manuscript writing. TF advised on study performance and manuscript preparation. MR helped with the ethics application and patient calculations, performed all statistical analysis and helped writing the manuscript. AZ wrote the initial trial proposal, coordinated and designed the study, recruited patients and wrote the final manuscript. All authors have read and approved the manuscript.

**Funding**

One Leo-Sound Sound Machine was provided free of charge and the publication fee was provided by Heine und Löwenstein. There was no scientific input of Heine and Löwenstein into the study plan and design, and no input into performance of study, analysis of data, interpretation of data or content of manuscript preparation.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Ethics approval was obtained for the study from the local ethics committee the Ethics committee of the City of Vienna – Gesundheitsdienst Stadt Wien (Reference Number: EK 17-149-0817). Written informed consent was obtained from all participants and all parents or guardians for participants under the age of 14 years, respectively.
Consent for publication
Not applicable.

Competing interests
FG has received an unrestricted Grant for different study from Gilead and AZ has received financial compensation for participation in advisory boards for Vertex, Novartis, Chiesi, Gilead AOP, and lecture fees from Hagleitner Hygiene, Astra Zeneca and Heine und Löwenstein. CL has received lecture fees from Novartis. ML, LR, CM, KK, TF and MR declare that they have no conflict of interest.

Author details
1Klinikum Favoriten, Wiener Gesundheitsverbund, Wien, Austria. 2Wilhelminenspital, Klinikum Ottakring, Department of Pediatrics and Adolescent Medicine, Teaching Hospital of the University of Vienna, Montleartstrasse 37, 1160 Wien, Austria. 3Department for Pediatric Cardiology and Intensive Care Medicine, University Hospital Göttingen, Göttingen, Germany. 4Faculty of Medicine, Sigmund Freud University, Vienna, Austria. 5Vienna Hospital Association, Healthcare Management, Vienna, Austria.

Received: 4 September 2020 Accepted: 1 December 2020
Published online: 12 December 2020

References
1. Whitburn S, Costelloe C, Montgomery AA, Redmond NM, Fletcher M, Peters TJ, et al. The frequency distribution of presenting symptoms in children aged six months to six years to primary care. Prim Health Care Res Dev. 2011;12(2):123–34.
2. Schappp NJ, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2001;1169:1–38.
3. Falcorner A, Oldman C, Helms P. Poor agreement between reported and recorded nocturnal cough in asthma. Pediatr Pulmonol. 1995;15(4):209–11.
4. Dales RE, White J, Bhumgara C, McMullen E. Parental reporting of children’s coughing is biased. Eur J Pediatr. 1997;156(3):541–5.
5. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(Suppl II):S265–835.
6. Cuppari C, et al. Allergen immunotherapy, routes of administration and cytokine networks: an update. Immunotherapy. 2014;6(6):775–86.
7. Bentur L, Beck R, Shinawi M, Naveh T, Gavriely N. Wheeze monitoring in children: current goals and unmet needs. Pediatr Allergy Immunol. 2020;31(S24):40.
8. Meijer GG, Postma DS, Wempe JB, Gerritsen J, Knol K, van Aalderen WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
9. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med. 1989;86(4):634–47.
10. Meijer GG, Poets DM, Wempe JB, Gerritsen J, Knol K, van Aalderen WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
11. Tierney WM, BH. Chronic cough in asthma. Am J Respir Crit Care Med. 1994;149(2 Pt 2):S136–7.
12. Schappp NJ, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2001;1169:1–38.
13. Bentur L, Beck R, Shinawi M, Naveh T, Gavriely N. Wheeze monitoring in children: assessment of nocturnal asthma and response to therapy. Eur Respir J. 2003;21(4):621–6.
14. Meier GG, Postma DM, Wempe JB, Gerritsen J, Knoll K, van Aalderen WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
15. Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med. 1989;86(4):634–47.
16. Meier GG, Poets DM, Wempe JB, Gerritsen J, Knol K, van Aalderen WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
17. Barton A, Gaydecki P, Holt K, Smith JA. Data reduction for cough studies using distribution of audio frequency content. Cough. 2012;8(1):12.
18. Spinou A, Biring SS. An update on measurement and monitoring of cough: what are the important study endpoints? J Thorac Dis. 2014;6(Suppl 7):S72–8.
19. Koehler U, Hildebrandt O, Nell C, Alahkra R, Nikolazik W, Weissflog A, et al. Akustisches Langzeit-monitoring von Atem- und Lungengerauschen im Schlaf: Warum ist das sinnvoll? Sommologie – Schlafmedizin und Schlaflforschung. 2014;18(4):225–30.
20. Koehler U, Hildebrandt O, Walliczek-Dworschak U, Nikolazik W, Weissflog A, Urban C, et al. Chronischer Husten – Neue diagnostische Perspektiven? DMW. 2017;142(01):47–53.
21. Koehler U, Brandenburg U, Weissflog A, Schrabei K, Grob V. LEOSound, an innovative procedure for acoustic long-term monitoring of asthmatic symptoms (wheezing and coughing) in children and adults. Pneumologie. 2014;68(4):277–81.
22. Desager KN, Nelen V, Weyler JJ, De Backer WA. Sleep disturbance and daytime symptoms in wheezing school-aged children. J Sleep Res. 2005; 14(1):77–82.
23. Cardinale F, Ciprandi G, Barberi S, Bernardini R, Caffaelli C, et al. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 2020;46(1):84.
24. Clifford RD, Rafdor M, Howell JB, Holgate ST. Prevalence of respiratory symptoms among 7 and 11 year old schoolchildren and association with asthma. Arch Dis Child. 1989;64(9):1119–25.
25. Pijnenburg MW, Baraldi E, Brandi LP, Carlso K-H, Ebert E, Frischer T, et al. Monitoring asthma in children. Eur Respir J. 2015;45(4):906–25.
26. Licitra A, Manti S, Chiappini E, Ciprandi G, Marsaglia GL. Severe asthma in children: current goals and unmet needs. Pediatr Allergy Immunol. 2020; 31(S24):40–2.
27. Licitra A, Manti S, Castagnoli R, Leonardi S, Marsaglia GL. Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice. Breathe. 2020;16(1):90301.
28. Leonardi S, Ciprandi G, Lanzafame A, Attardo D, Tardino L, Parisi G, et al. Exhaled breath temperature in asthmatic children. J Biol Regul Homeost Agents. 2015;29(1 Suppl 1):47–54.
29. Haq UI, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in children. BMJ. 2017;2:686.
30. Southen KW, Merelle MM, Dantert-Roelse JE, Nagelkerke AD. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev. 2009;2009(1):CD001402.
31. Knapp EA, Fink AK, Goss CH, Seval A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. Annals ATS. 2016;13(7):1173–9.
32. Castellani C, Duff AJA, Bell SC, Heijeman HGM, Munck A, Ratjen F, et al. EFCs best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–78.
33. Mantsi T, Tosca MA, Licitra A, Brambilli I, Foidaletti T, Ciprandi G, et al. Cough remedies for children and adolescents: current and future perspectives. Paediart Drugs. 2020;102(2):91–5.
34. Ramanuja S, Kelkar P. Habit cough. Ann Allergy Asthma Immunol. 2009;102(2):91–5.
35.TURNER-WARWICK M. Epidemiology of nocturnal asthma. Am J Med. 1988;102(2):91–5.
36. MODEL R. Habit cough. Ann Allergy Asthma Immunol. 2009;102(2):91–5.
37. MEIJER GG, POSTMA DM, WEMPE JB, GERRITSEN J, KNOB K, VAN AALDEREN WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
38. TURNER-WARWICK M. Epidemiology of nocturnal asthma. Am J Med. 1989;86(4):634–47.
39. SCHAPPP NJ, RECHTSTEINER EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat. 2001;1169:1–38.
40. MEIJER GG, POSTMA DM, WEMPE JB, GERRITSEN J, KNOB K, VAN AALDEREN WM. Frequency of nocturnal symptoms in asthmatic children attending a hospital outpatient clinic. Eur Respir J. 1995;8(12):2076–80.
41. TURNER-WARWICK M. Epidemiology of nocturnal asthma. Am J Med. 1989;86(4):634–47.
41. Hartnick CJ, Zurakowski D, Haver K. Validation of a pediatric cough questionnaire. Ear Nose Throat J. 2009;88(11):1213–7.
42. Newcombe PA, Sheffield JK, Petsky HL, Marchant JM, Willis C, Chang AB. A child chronic cough-specific quality of life measure: development and validation. Thorax. 2016;71(8):695–700.
43. Bliring SS, Fleming T, Matos S, Raj AA, Evans DH, Pavord ID. The Leicester cough monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J. 2008;31(5):1013–8.
44. Al-Shamrani A, Bagais K, Alenazi A, Alqwaiee M, Al-Harbi AS. Wheezing in children: approaches to diagnosis and management. Int J Pediatr Adolesc Med. 2019;6(2):68–73.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.